Ikena Oncology, Inc. (NASDAQ:IKNA) Position Lifted by BML Capital Management LLC

BML Capital Management LLC raised its position in shares of Ikena Oncology, Inc. (NASDAQ:IKNA - Free Report) by 395.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,585,866 shares of the company's stock after acquiring an additional 2,862,578 shares during the period. Ikena Oncology makes up about 3.7% of BML Capital Management LLC's investment portfolio, making the stock its 10th largest position. BML Capital Management LLC owned 7.43% of Ikena Oncology worth $5,881,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. FMR LLC boosted its stake in shares of Ikena Oncology by 94.1% during the 3rd quarter. FMR LLC now owns 38,374 shares of the company's stock worth $66,000 after purchasing an additional 18,607 shares during the period. BBR Partners LLC lifted its stake in Ikena Oncology by 550.0% in the third quarter. BBR Partners LLC now owns 130,000 shares of the company's stock worth $225,000 after purchasing an additional 110,000 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Ikena Oncology by 5.6% during the third quarter. Geode Capital Management LLC now owns 271,026 shares of the company's stock valued at $469,000 after buying an additional 14,319 shares during the period. Peapod Lane Capital LLC bought a new position in shares of Ikena Oncology during the fourth quarter valued at approximately $833,000. Finally, NEA Management Company LLC raised its holdings in shares of Ikena Oncology by 5.3% in the third quarter. NEA Management Company LLC now owns 600,063 shares of the company's stock worth $1,038,000 after buying an additional 30,013 shares during the period. Hedge funds and other institutional investors own 75.00% of the company's stock.

Remove Ads

Analysts Set New Price Targets

IKNA has been the subject of a number of recent analyst reports. Wedbush restated a "neutral" rating and set a $2.00 price objective on shares of Ikena Oncology in a report on Monday, December 23rd. HC Wainwright reissued a "buy" rating and set a $4.00 target price on shares of Ikena Oncology in a research note on Monday, November 11th.

Ikena Oncology Price Performance

IKNA stock traded down $0.03 during mid-day trading on Tuesday, reaching $1.38. The company had a trading volume of 36,470 shares, compared to its average volume of 198,729. The company has a market capitalization of $66.60 million, a PE ratio of -1.12 and a beta of 0.49. The firm has a 50 day moving average of $1.48 and a 200 day moving average of $1.62. Ikena Oncology, Inc. has a 12 month low of $1.22 and a 12 month high of $1.94.

Ikena Oncology (NASDAQ:IKNA - Get Free Report) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. Analysts anticipate that Ikena Oncology, Inc. will post -0.91 EPS for the current year.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.